Amy Burroughs appointed as Terns Pharmaceuticals CEO after leading Cleave Pharmaceuticals. Amy Burroughs nombrada directora ejecutiva de Terns Pharmaceuticals después de liderar Cleave Pharmaceuticals.

Terns Pharmaceuticals has appointed Amy Burroughs as its new Chief Executive Officer. Terns Pharmaceuticals ha nombrado a Amy Burroughs como su nueva directora ejecutiva. Burroughs, who previously worked at Cleave Pharmaceuticals and Crinetics Pharmaceuticals, will also join Terns' board of directors. Burroughs, que anteriormente trabajó en Cleave Pharmaceuticals y Crinetics Pharmaceuticals, también se unirá a la junta directiva de Terns. She served as the CEO of Cleave Pharmaceuticals from April 2019 to October 2023. Se desempeñó como directora ejecutiva de Cleave Pharmaceuticals desde abril de 2019 hasta octubre de 2023. This appointment follows Terns' recent achievements in developing a portfolio of small-molecule product candidates to address serious diseases, such as oncology and obesity. Este nombramiento se produce tras los recientes logros de Terns en el desarrollo de una cartera de productos candidatos de moléculas pequeñas para abordar enfermedades graves, como la oncología y la obesidad.